biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Hunter Syndrome

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Jun 27, 2022 8:04am

212 Views

Post# 34783974

Hunter Syndrome

With BTI designating Hunter Syndrome as its lead xB3 candidate for clinical trials with expectation of initiation of human trials just over one year from now that could speak to how the relationship with Chiesi is progressing. With Hunter Syndrome as its lead BTI is going head-to-head against Denali which already has Hunter Syndrome in human clinical trials. BTI also has Gaucher's Disease in development with Oxyrane which is the most common Lysosomal Storage Disorder. From Hunter Syndrome, to Gaucher's Disease, to Chiesi Lysosomal Storage Disorders are a strategic focus and BTI wants to go head-to-head vs. Denali.

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia